Michael Kattan, Ph.D.

Surgeon:

No

Treats:

Adults Only

Michael W. Kattan, MBA, PhD, is Chairman, Department of Quantitative Health Sciences, at Cleveland Clinic's main campus; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland; Professor, Division of General Medical Sciences - Oncology, Cancer Center, School of Medicine, Case Western Reserve University; and Professor, Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University. The Department of Quantitative Health Sciences comprises more than 90 individuals committed to the conduct of quantitative research in healthcare; more detail is available at www.clevelandclinic.org/qhs.  Dr. Kattan graduated with a master's degree in business administration from the University of Arkansas, Fayetteville, and a doctorate of philosophy in business administration from the University of Houston in Texas. He completed training as a postdoctoral fellow in medical informatics at Baylor College of Medicine, Houston, Texas.

Dr. Kattan is a member of the American Statistical Association and has held several posts with the Society for Medical Decision Making, most recently receiving the Eugene L. Saenger Award for Distinguished Service. He is or has recently been on the editorial boards for 12 journals: Cancer Investigation, Nature Clinical Practice Urology, Medical Decision Making, Clinical Genitourinary Cancer, Urologic Oncology, Frontiers in Urogenital Cancer, Personalized Medicine in Oncology, European Urology, US Urology, Annals of Urology, Journal of Urology, and Journal of Clinical Oncology.

Dr. Kattan has coauthored over 400 articles in peer-reviewed journals. His work is well cited, resulting in his h-index of 70. His research is primarily focused on the development, validation, and use of prediction models. Most of these models are available online, and designed for physician use, at http://rcalc.ccf.org/. Dr. Kattan is also interested in quality of life assessment to support medical decision making (such as utility assessment), decision analysis, cost-effectiveness analysis, and comparative effectiveness. He is a standing member of the NIH Epidemiology in Cancer study section.

Within Cleveland Clinic, Dr. Kattan chairs the Outcomes Books Editorial Board. This review panel provides critique and feedback for the various Outcomes books published by Cleveland Clinic and available online at http://my.clevelandclinic.org/about-cleveland-clinic/quality-patient-safety/treatment-outcomes.aspx. In addition, Dr. Kattan is the Principal Investigator for the Optimizing Healthcare Decision Making strategic initiative. This group provides Cleveland Clinic investigators with datasets from the electronic health record for the purposes of inclusion in outcomes books, grant proposals, or research articles.

Furthermore, Dr. Kattan serves on the Commercialization Council for Cleveland Clinic Innovations. The Council advises on internal strategy in promoting innovation and commercialization, as well as approves internal commercialization grants.

Dr. Kattan’s CV is available here.

Doctorate - University of Houston

Management of Information Systems
Houston, TX USA
1993

Graduate - University of Arkansas, Fayetteville

Computer Information Systems/Quantitative Analysis
Fayetteville, AR USA
1989

Undergraduate - University of Arkansas, Fayetteville

Food Science
Fayetteville, AR USA
1987

• The Eugene L. Saenger Award for Distinguished Service to Society of Medical Decision Making (2008)

Patents Awarded:

• “A Nomogram to Aid in the Decision to Treat Clinically Localized Prostate Cancer.” 1999, US Patent No: 5,993,388
• "Nomograms to Aid in the Treatment of Prostatic Cancer." 2002, US Patent No: 6,409,664

Patents Published:

• “Method to determine outcome for patients with prostatic disease.” 2003, US Patent Publication Number: 20030235816
• “Methods to predict death from breast cancer.” 2005, US Patent Publication Number: 20050019798
• “Methods to predict additional nodal metastases in breast cancer patients.” 2005, US Patent Publication Number: 20050282146
• “Method to predict prostate cancer.” 2005, US Patent Publication Number: 20050282199
• “Method to predict positive repeat prostate biopsy.” 2007, US Patent Publication Number: 20070111269
• “Method to predict risk of BPH progression.” 2007, US Patent Pulication Number: 20070134725

• Society for Medical Decision Making
• American Statistical Association

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 8/23/2010, Dr. Kattan has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting. Dr. Kattan receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:

• Express Scripts, Inc.

• English